StockNews.AI
SRTS
StockNews.AI
2 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS

1. Pomerantz LLP is investigating potential securities fraud at Sensus Healthcare. 2. Sensus missed Q2 earnings estimates by $0.09 and revenue estimates by $2M. 3. Q2 revenue fell 20.7% year-over-year, primarily due to fewer units sold. 4. Sensus's stock declined 35.32% to $3.46 following the disappointing financial results. 5. The ongoing investigation suggests potential legal troubles for Sensus management.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The stock's significant drop in response to poor earnings and potential fraud indicates severe investor concern.

How important is it?

The investigation and financial misses represent critical risks that could affect SRTS's market perception significantly.

Why Short Term?

The immediate market reaction suggests volatility in the near term due to ongoing legal concerns, as seen with similar cases.

Related Companies

SRTSAAPLTSLAMSFT
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sensus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 7, 2025, Sensus reported its financial results for the second quarter of 2025, revealing a second quarter GAAP earnings-per-share figure of -$0.06, missing estimates by $0.09, and revenue of $7.3M, representing a -20.7% year-over-year decline and missing estimates by $2M. Sensus attributed the decrease in revenue primarily to a lower number of units sold to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements. On this news, Sensus’s stock price fell $1.89 per share, or 35.32%, to close at $3.46 per share on August 8, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News